Frontiers in medicine · 2026
Frailty and lived experiences in older adults with osteoporosis: protocol for a convergent mixed-methods study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jinli, Gao Xinling, Li Shuang, Lin Mei, Lan Yaqi, Tan Zhen, Liu Pei
Аннотация
BACKGROUND: Older adults is characterized by an age-related decline in bone mineral density. Frailty-a distinct age-associated geriatric syndrome-further exacerbates this condition. The concomitance of osteoporosis and frailty in older adults markedly heightens the risk of functional decline, with attendant profound psychosocial sequelae. A mixed-methods study design is essential to achieve a comprehensive, patient-centered understanding of this phenomenon.
METHODS: This study will adopt a convergent mixed-methods design comprising three primary phases: (1) Quantitative phase: a cross-sectional survey will be conducted among older adults diagnosed with osteoporosis. Data collection will include demographic variables, scores from the Edmonton Frail Scale, Activities of Daily Living assessments, Nutritional Risk Screening assessments, and the Hospital Anxiety and Depression Scale. In addition, handgrip strength will be measured, alongside relevant laboratory parameters. Data will undergo descriptive analysis, followed by univariate analyses and multivariate binary logistic regression to identify factors associated with frailty. (2) Qualitative phase: semi-structured, face-to-face interviews will be performed with participants classified as frail according to their frailty assessment scores, enabling an in-depth exploration of their subjective perceptions and experiences of frailty within the context of osteoporosis. (3) Integration phase: key findings from both quantitative and qualitative components will be analyzed and synthesized to generate a comprehensive understanding of the phenomenon.
DISCUSSION: This study aims to explore the prevalence and clinical characteristics of frailty among older adults with osteoporosis. It also seeks to identify associated risk factors and to explore patients' subjective experiences of living with frailty in the context of osteoporosis.
CLINICAL TRIAL REGISTRATION: This trial has been registered with the Chinese Clinical Trial Registry (ChiCTR2500097059).
METHODS: This study will adopt a convergent mixed-methods design comprising three primary phases: (1) Quantitative phase: a cross-sectional survey will be conducted among older adults diagnosed with osteoporosis. Data collection will include demographic variables, scores from the Edmonton Frail Scale, Activities of Daily Living assessments, Nutritional Risk Screening assessments, and the Hospital Anxiety and Depression Scale. In addition, handgrip strength will be measured, alongside relevant laboratory parameters. Data will undergo descriptive analysis, followed by univariate analyses and multivariate binary logistic regression to identify factors associated with frailty. (2) Qualitative phase: semi-structured, face-to-face interviews will be performed with participants classified as frail according to their frailty assessment scores, enabling an in-depth exploration of their subjective perceptions and experiences of frailty within the context of osteoporosis. (3) Integration phase: key findings from both quantitative and qualitative components will be analyzed and synthesized to generate a comprehensive understanding of the phenomenon.
DISCUSSION: This study aims to explore the prevalence and clinical characteristics of frailty among older adults with osteoporosis. It also seeks to identify associated risk factors and to explore patients' subjective experiences of living with frailty in the context of osteoporosis.
CLINICAL TRIAL REGISTRATION: This trial has been registered with the Chinese Clinical Trial Registry (ChiCTR2500097059).